Home LiteratureArticle Details
PMID: 15194567 Published · ppublish English Journal Article

TNFalpha therapy in psoriatic arthritis and psoriasis.

Annals of the rheumatic diseases ·Vol. 63 ·No. 7 ·2004-07-00 ·Pages 755-8

Mease P

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal/therapeutic use Antirheumatic Agents/therapeutic use Arthritis, Psoriatic/drug therapy,immunology,pathology Arthritis, Rheumatoid/immunology Etanercept Humans Immunoglobulin G/therapeutic use Infliximab Psoriasis/drug therapy,immunology,pathology Receptors, Tumor Necrosis Factor/therapeutic use Tumor Necrosis Factor-alpha/antagonists & inhibitors,immunology
Chemicals
Antibodies, Monoclonal Antirheumatic Agents Immunoglobulin G Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Infliximab Etanercept
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Mease P
Seattle Rheumatology Associates, Seattle, WA 98104, USA. [email protected]
References (55)
55 references, click to expand
  1. Etanercept as monotherapy in patients with psoriasis.
    N Engl J Med. 2003 Nov 20;349(21):2014-22 PMID: 14627786
  2. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
    Arch Dermatol. 2001 Mar;137(3):280-4 PMID: 11255325
  3. A randomized trial of etanercept as monotherapy for psoriasis.
    Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632 PMID: 14676082
  4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    J Rheumatol. 2003 Dec;30(12):2563-71 PMID: 14719195
  5. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Ann Rheum Dis. 2004 Jul;63(7):769-73 PMID: 15194570
  6. Psoriatic arthritis.
    Semin Arthritis Rheum. 1973;3(1):55-78 PMID: 4581554
  7. Psoriatic arthritis in psoriatic patients.
    Br J Rheumatol. 1984 Nov;23(4):246-50 PMID: 6487929
  8. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.
    J Exp Med. 1985 Dec 1;162(6):2163-8 PMID: 2999289
  9. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.
    Nature. 1986 Feb 6-12;319(6053):516-8 PMID: 3511389
  10. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.
    Nature. 1986 Aug 7-13;322(6079):547-9 PMID: 3736671
  11. Psoriatic arthritis (PSA)--an analysis of 220 patients.
    Q J Med. 1987 Feb;62(238):127-41 PMID: 3659255
  12. Implications from the occurrence of Reiter's syndrome and related disorders in association with advanced HIV infection.
    Scand J Rheumatol Suppl. 1988;74:89-93 PMID: 3266029
  13. The role of cytokines in chondrocyte mediated cartilage degradation.
    J Rheumatol Suppl. 1989 Aug;18:32-4 PMID: 2810294
  14. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report.
    Acta Derm Venereol Suppl (Stockh). 1989;146:69-71 PMID: 2609889
  15. Longitudinal study of clinical and radiological progression in psoriatic arthritis.
    J Rheumatol. 1990 Jun;17(6):809-12 PMID: 2388203
  16. Tumor necrosis factor.
    J Am Acad Dermatol. 1991 May;24(5 Pt 1):675-85 PMID: 1869638
  17. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
    Med Care. 1992 Jun;30(6):473-83 PMID: 1593914
  18. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis.
    Arthritis Rheum. 1993 Jul;36(7):893-900 PMID: 7686370
  19. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.
    Clin Exp Immunol. 1994 Apr;96(1):146-51 PMID: 8149659
  20. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity.
    Clin Exp Dermatol. 1994 Sep;19(5):383-7 PMID: 7955493
  21. Prevalence of psoriatic arthritis in Italian psoriatic patients.
    J Rheumatol. 1995 Aug;22(8):1499-503 PMID: 7473473
  22. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.
    Arthritis Rheum. 1996 Jul;39(7):1077-81 PMID: 8670314
  23. Role of cytokines in rheumatoid arthritis.
    Annu Rev Immunol. 1996;14:397-440 PMID: 8717520
  24. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
    Dermatol Clin. 1996 Jul;14(3):485-96 PMID: 8818558
  25. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
    J Rheumatol. 1997 Mar;24(3):518-23 PMID: 9058659
  26. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    N Engl J Med. 1997 Oct 9;337(15):1029-35 PMID: 9321530
  27. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.
    Arthritis Rheum. 1997 Oct;40(10):1868-72 PMID: 9336423
  28. Patterns of cytokine production in psoriatic synovium.
    J Rheumatol. 1998 Aug;25(8):1544-52 PMID: 9712099
  29. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Arthritis Rheum. 1998 Sep;41(9):1552-63 PMID: 9751087
  30. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    N Engl J Med. 1999 Jan 28;340(4):253-9 PMID: 9920948
  31. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
    Ann Intern Med. 1999 Mar 16;130(6):478-86 PMID: 10075615
  32. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis.
    Arthritis Rheum. 1999 Jul;42(7):1481-4 PMID: 10403277
  33. Psoriasis causes as much disability as other major medical diseases.
    J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7 PMID: 10459113
  34. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Lancet. 1999 Dec 4;354(9194):1932-9 PMID: 10622295
  35. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis.
    Arch Dermatol Res. 1998 May;290(5):246-52 PMID: 9681675
  36. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis.
    Arthritis Rheum. 2001 Apr;45(2):151-8 PMID: 11324779
  37. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
    Lancet. 2001 Jun 9;357(9271):1842-7 PMID: 11410193
  38. The immunologic basis for the treatment of psoriasis with new biologic agents.
    J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6 PMID: 11756941
  39. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
    Lancet. 2002 Apr 6;359(9313):1187-93 PMID: 11955536
  40. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    N Engl J Med. 2002 May 2;346(18):1349-56 PMID: 11986408
  41. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
    Lancet. 2002 May 4;359(9317):1541-9 PMID: 12047962
  42. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
    Arthritis Rheum. 2002 Jun;46(6):1443-50 PMID: 12115173
  43. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation.
    Arthritis Rheum. 2002 Oct 15;47(5):506-12 PMID: 12382299
  44. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
    J Am Acad Dermatol. 2003 Jan;48(1):68-75 PMID: 12522373
  45. Angiopoietins, growth factors, and vascular morphology in early arthritis.
    J Rheumatol. 2003 Feb;30(2):260-8 PMID: 12563678
  46. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.
    J Clin Invest. 2003 Mar;111(6):821-31 PMID: 12639988
  47. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis.
    J Drugs Dermatol. 2002 Dec;1(3):264-75 PMID: 12851985
  48. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Arthritis Rheum. 2003 Nov;48(11):3230-6 PMID: 14613288
  49. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
    J Rheumatol. 2000 May;27(5):1247-50 PMID: 10813295
  50. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
    Arthritis Rheum. 2000 Jun;43(6):1244-56 PMID: 10857783
  51. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Lancet. 2000 Jul 29;356(9227):385-90 PMID: 10972371
  52. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
    N Engl J Med. 2000 Nov 30;343(22):1586-93 PMID: 11096165
  53. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    N Engl J Med. 2000 Nov 30;343(22):1594-602 PMID: 11096166
  54. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis.
    Ann Rheum Dis. 2001 Apr;60(4):316-21 PMID: 11247858
  55. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
    Ann Rheum Dis. 2003 Dec;62(12):1168-77 PMID: 14644854
Article Info
Journal
Annals of the rheumatic diseases
Abbr.
Ann Rheum Dis
ISSN
0003-4967
DOI
10.1136/ard.2004.020719
Email
[email protected]
Published
2004-07-00
Pages
755-8
Language
English
Region
England
NLM ID
0372355
PMCID
PMC1755077
Subset
IM
External Links
PubMed source DOI: 10.1136/ard.2004.020719 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2